Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Nat Genet. Author manuscript; available in PMC 2011 March 1.
Published in final edited form as:
Published online 2010 August 15. doi:  10.1038/ng.646
PMCID: PMC2930028

Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome


We demonstrate the successful application of exome sequencing13 to discover a gene for an autosomal dominant disorder, Kabuki syndrome (OMIM %147920). The exomes of ten unrelated probands were subjected to massively parallel sequencing. After filtering against SNP databases, there was no compelling candidate gene containing novel variants in all affected individuals. Less stringent filtering criteria permitted modest genetic heterogeneity or missing data, but identified multiple candidate genes. However, genotypic and phenotypic stratification highlighted MLL2, a Trithorax-group histone methyltransferase4, in which seven probands had novel nonsense or frameshift mutations. Follow-up Sanger sequencing detected MLL2 mutations in two of the three remaining cases, and in 26 of 43 additional cases. In families where parental DNA was available, the mutation was confirmed to be de novo (n = 12) or transmitted (n = 2) in concordance with phenotype. Our results strongly suggest that mutations in MLL2 are a major cause of Kabuki syndrome.

Kabuki syndrome is a rare, multiple malformation disorder characterized by a distinctive facial appearance (Supplementary Fig. 1), cardiac anomalies, skeletal abnormalities, immunological defects, and mild to moderate mental retardation. Originally described by Niikawa et al.5 and Kuroki et al.6 in 1981, Kabuki syndrome has an estimated incidence of 1 in 32,0007 and about 400 cases have been reported worldwide. The vast majority of reported cases have been sporadic, but parent-to-child transmission in more than a half a dozen instances8 suggests that Kabuki syndrome is an autosomal dominant disorder. The relatively low number of cases, the lack of multiplex families, and the phenotypic variability of Kabuki syndrome have made the identification of the gene(s) underlying Kabuki syndrome intractable to conventional approaches of gene discovery, despite aggressive efforts.

We sequenced the exomes of ten unrelated individuals with Kabuki syndrome, seven of European ancestry, two of Hispanic ancestry, and one of mixed European/Haitian ancestry (Supplementary Fig. 1, Supplementary Table 1). Enrichment was performed by hybridization of shotgun fragment libraries to custom microarrays, followed by massively parallel sequencing13. On average, 6.3 gigabases of sequence were generated per sample to achieve 40× coverage of the mappable, targeted exome (31 megabases). As previously, our analyses focused primarily on nonsynonymous (NS) variants, splice acceptor and donor site mutations (SS) and coding indels (I), anticipating that synonymous variants were far less likely to be pathogenic. We also predicted that variants underlying Kabuki syndrome are rare, and therefore likely to be novel. Novelty was defined here by absence from all datasets used for comparison, including dbSNP129, the 1000 Genomes Project, exome data from sixteen individuals previously reported by us2,3, and ten exomes sequenced as part of the Environmental Genome Project (EGP).

Under a dominant model in which each case was required to have at least one novel NS/SS/I variant in the same gene, only a single candidate gene (MUC16) was shared by all ten exomes (Table 1, row 4; Supplementary Table 2). However, MUC16 was considered likely to be a false positive due to its extremely large size (14,507 aa). Potential explanations for our failure to find a compelling candidate gene in which novel variants are observed in all affected individuals included: (a) that Kabuki syndrome is genetically heterogeneous, and therefore not all affected individuals will have mutations in the same gene; (b) that we failed to identify all mutations in the targeted exome; (c) that some or all causative mutations were outside of the targeted exome, e.g., in non-coding regions or unannotated genes. To allow for a modest degree of genetic heterogeneity and/or missing data, we conducted a less stringent analysis by looking for candidate genes shared among subsets of affected individuals. Specifically, we searched for subsets of x out of 10 exomes having ≥ 1 novel variant in the same gene, for x = 1 to 10. For x = 9, 8, and 7, novel variants were shared in three genes, six genes, and sixteen genes, respectively (Table 1, row 4). However, there was no obvious way to rank these candidates.

Table 1
Number of genes common to any subset of x affected individuals

We speculated that genotypic and/or phenotypic stratification would facilitate the prioritization of candidate genes identified by subset analysis. Specifically, we assigned a categorical rank to each Kabuki case based on a subjective assessment of the presence of, or similarity to, the canonical facial characteristics of Kabuki syndrome (Supplementary Fig. 1) and the presence of developmental delay and/or major birth defects (Supplementary Table 1). The highest ranked case was one of a pair of monozygotic twins with Kabuki syndrome. We then categorized the functional impact (i.e. nonsense versus nonsynonymous substitution, splice-site disruption, frameshift versus in-frame indel) of each novel variant in candidate genes shared by each subset of two or more ranked cases. Manual review of these data highlighted distinct, novel nonsense variants in MLL2 in each of the four highest ranked cases. On sequential analysis of phenotype-ranked cases with a loss-of-function filter, MLL2 is the only candidate gene remaining after addition of the second individual (Table 2, row 5, column "+2"). No novel variant in MLL2 was found in the Kabuki case ranked 5th, such that the number of candidate genes drops to zero after the fourth individual (Table 2, row 5). However, a 4-bp deletion was found in the case ranked 6th and nonsense variants in the cases ranked 7th and 9th. Thus, exome sequencing identified a nonsense substitution or frameshift indel in MLL2 in seven of the ten Kabuki cases.

Table 2
Number of genes common in sequential analysis of phenotypically ranked individuals

Retrospectively, if we apply a loss-of-function filter to the subset analysis of exome data (Table 1, row 5), at x = 7, MLL2 is the only candidate gene. We also developed a post hoc ranking of candidate genes based on functional impact of variants present (“variant score”) and the rank of the cases in which each variant was observed (“case score”). When applied to the exome data as a combined metric, MLL2 emerges as the top candidate (Supplementary Fig. 2).

In parallel with these analyses, we applied genomic evolutionary rate profiling (GERP)9 to exome data. GERP uses mammalian genome alignments to define a rejected substitution (RS) score for each variant, regardless of functional class. We have previously shown that the quantitative ranking of candidate genes by the RS scores of their novel variants can facilitate the exome-based analysis of Mendelian disorders10. In subset analysis with GERP-based ranking, MLL2 remains on the candidate list up to x = 8, ranking 3rd in a list of 11 candidate genes at this threshold (Table 3, Supplementary Fig. 3). Interestingly, the additional MLL2 variant contributing to this analysis (such that MLL2 is still considered at x = 8) is a synonymous substitution with an RS score of 0.368 in the 5th ranked case.

Table 3
Analysis of exome variants using genomic evolutionary rate profiling

We sought to confirm all novel variants identified in MLL2, particularly because loss-of-function variants identified through massively parallel sequencing have a higher prior probability of being false positives. All seven loss-of-function variants in MLL2 were validated by Sanger sequencing. We further analyzed the three cases in which we did not initially find a loss-of-function variant in MLL2, first by array comparative genomic hybridization (aCGH) to determine any gross structural changes, and then by Sanger sequencing of all exons of MLL2 in case of false negatives by exome sequencing. Since an average of 96% of coding bases in MLL2 were called at sufficient quality and coverage for single-nucleotide variant detection, we anticipated that any missed variants were more likely to be indels instead, because of the higher coverage required for confident indel detection in short-read sequence data. Indeed, although aCGH did not find any structural variants in the region, Sanger sequencing did identify frameshift indels in two of these three cases (ranked 8th and 10th).

Ultimately, loss-of-function mutations in MLL2 were identified in nine out of ten cases in the discovery cohort (Fig. 1), making it a compelling candidate for Kabuki syndrome. For validation, we screened all 54 exons of MLL2 in 43 additional cases by Sanger sequencing. Novel nonsynonymous, nonsense or frameshift mutations in MLL2 were found in 26 of these 43 cases (Fig. 1 and Supplementary Table 3). In total, through either exome sequencing or targeted sequencing of MLL2, 33 distinct MLL2 mutations were identified in 35 of 53 families (66%) with Kabuki syndrome (Fig. 1 and Supplementary Table 3). In each of twelve cases for which DNA from both parents was available, the MLL2 variant was found to have occurred de novo. Three mutations were found in two cases each: one mutation was confirmed to have arisen de novo in one of the cases, indicating that some mutations are recurrent. Novel MLL2 mutations (K4527X and T5464M) were also identified in each of two families in which Kabuki syndrome was transmitted from parent-to-child. None of the additional MLL2 mutations were found in 190 control chromosomes from individuals of matched geographical ancestry.

Figure 1
Genomic structure and allelic spectrum of MLL2 mutations that cause Kabuki syndrome

Our results strongly suggest that mutations in MLL2 are a major cause of Kabuki syndrome. MLL2 encodes a large 5,262 residue protein that is part of the SET family of proteins, of which Trithorax, the Drosophila homologue of MLL, is the best characterized11. The SET domain of MLL2 confers strong histone 3 lysine 4 methyltransferase activity and is important in the epigenetic control of active chromatin states12. Murine loss of Mll2 on a mixed 129Sv/C57BL/6 background slows growth, increases apoptosis and retards development leading to early embryonic lethality, due in part to mis-regulation of homeobox gene expression13. However, no morphological defects have been reported in Mll2+/− mice13.

Most of the MLL2 variants identified in Kabuki cases are predicted to truncate the polypeptide chain before translation of the SET domain. Accordingly, though it is not certain whether Kabuki syndrome results from haploinsufficiency or a gain-of function at MLL2, haploinsufficiency seems to be the more likely mechanism. Deletion of chromosome 12q12-q13.2, which encompasses MLL2, has been reported in a child with characteristics of Noonan syndrome14. However, we re-analyzed this case using oligo aCGH (including 21 probes that cover MLL2) and found the distal breakpoint to be located ~700 kb proximal of MLL2 (data not shown). Interestingly, all of the pathogenic missense variants identified herein are located in regions of MLL2 that encode C-terminal domains. This suggests that missense variants elsewhere in MLL2 could be better tolerated or, alternatively, are embryonic lethal.

For the 18 of 53 cases for which no novel protein-altering variant was found, it is possible that non-coding or other missed mutations in MLL2 are responsible instead. Alternatively, Kabuki syndrome could be genetically heterogeneous, and further analysis of these cases by exome sequencing may elucidate additional genes for Kabuki syndrome and potentially explain some of the phenotypic heterogeneity seen in this disease. Notably, 9 of 10 individuals in the discovery cohort (90%), but only 26 of 43 individuals in the replication cohort (60%), were ultimately found to have mutations in MLL2. It is therefore possible that the careful selection of canonical Kabuki cases for the discovery cohort enriched for a shared genetic basis. This underscores the importance of access to deeply phenotyped and well-characterized cases.

In summary, we applied exome sequencing of a small number of unrelated cases to discover that mutations in MLL2 underlie Kabuki syndrome. As predicted in previous analyses2,3, allowing for even a small degree of genetic heterogeneity or missing data significantly confounds exome analysis by increasing the number of candidate genes consistent with the model of inheritance. To facilitate the prioritization of genes under such criteria, we stratified data by ranked phenotypes and found that MLL2 was prominent in the higher ranked cases. However, nine of the ten Kabuki cases in the discovery cohort were ultimately found to have MLL2 mutations, such that stratification by phenotype was of less importance than originally appeared to be the case. Nonetheless, the sequential analysis of ranked cases may have reduced the probability of confounding due to genetic heterogeneity. All of the MLL2 mutations found in the discovery set via exome sequencing were loss-of-function variants. As a result, MLL2 ranked highly among candidates assessed by predicted functional impact. Such a pattern will likely occur for some, but not all, Mendelian phenotypes subjected to this approach. We anticipate that the further development of strategies to stratify data at both the genotypic and phenotypic level will be critical for exome and whole genome sequencing to reach their full potential as tools for discovery of genes underlying Mendelian and complex diseases.

Supplementary Material


We thank the families for their participation and the Kabuki Syndrome Network for their support. We thank J. Allanson, J. Carey, and M. Golabi for referral of cases and M. Emond for helpful discussion. We thank the 1000 Genomes Project for early data release that proved useful for filtering out common variants. Our work was supported in part by grants from the National Institutes of Health/National Heart Lung and Blood Institute (5R01HL094976 to D.A.N. and J.S.), the National Institutes of Health/National Human Genome Research Institute (5R21HG004749 to J.S., 1RC2HG005608 to M.J.B., D.A.N., and J.S.; and 5RO1HG004316 to H.K.T.), National Institute of Heath/National Institute of Environmental Health Sciences (HHSN273200800010C to D.N. and M.R.), Ministry of Health, Labour and Welfare (K.Y., N.M., T.O., and N.N.), Japan Science and Technology Agency (N.M.), Society for the Promotion of Science (N.M.), the Life Sciences Discovery Fund (2065508 and 0905001), the Washington Research Foundation, and the National Institutes of Health/National Institute of Child Health and Human Development (1R01HD048895 to M.J.B.). S.B.N. is supported by the Agency for Science, Technology and Research, Singapore. A.W.B. is supported by a training fellowship from the National Institutes of Health/National Human Genome Research Institute (T32HG00035).



Refseq 36.3 :

Phaster :

SeattleSeq Annotation :

1000 Genomes Project: :

Data access

Exome data for the discovery cohort will be available via the NCBI dbGaP repository.

Author contributions

The project was conceived and experiments planned by M.J.B., D.A.N., and J.S. Review of phenotypes and sample collection were performed by M.J.B., M.C.H., M.M., K.Y., N.M., T.O. and N.N. Experiments were performed by S.B.N., K.J.B., A.E.B., C.L., H.C.M. J.D.S., M.J.R., E.H.T., and H.G. Ethical consultation was provided by H.K.T. Data analysis was performed by A.W.B., M.J.B., K.J.B., G.M.C., S.B.N. and J.S. The manuscript was written by M.J.B., S.B.N., and J.S. All aspects of the study were supervised by M.J.B. and J.S.

Competing Interests Statement

The authors declare no competing financial interests.


1. Choi M, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci U S A. 2009;106:19096–19101. [PubMed]
2. Ng SB, et al. Exome sequencing identifies the cause of a mendelian disorder. Nat Genet. 2010;42:30–35. [PMC free article] [PubMed]
3. Ng SB, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature. 2009;461:272–276. [PMC free article] [PubMed]
4. FitzGerald KT, Diaz MO. MLL2: A new mammalian member of the trx/MLL family of genes. Genomics. 1999;59:187–192. [PubMed]
5. Niikawa N, Matsuura N, Fukushima Y, Ohsawa T, Kajii T. Kabuki make-up syndrome: a syndrome of mental retardation, unusual facies, large and protruding ears, and postnatal growth deficiency. J Pediatr. 1981;99:565–569. [PubMed]
6. Kuroki Y, Suzuki Y, Chyo H, Hata A, Matsui I. A new malformation syndrome of long palpebral fissures, large ears, depressed nasal tip, and skeletal anomalies associated with postnatal dwarfism and mental retardation. J Pediatr. 1981;99:570–573. [PubMed]
7. Niikawa N, et al. Kabuki make-up (Niikawa-Kuroki) syndrome: a study of 62 patients. Am J Med Genet. 1988;31:565–589. [PubMed]
8. Courtens W, Rassart A, Stene JJ, Vamos E. Further evidence for autosomal dominant inheritance and ectodermal abnormalities in Kabuki syndrome. Am J Med Genet. 2000;93:244–249. [PubMed]
9. Cooper GM, et al. Distribution and intensity of constraint in mammalian genomic sequence. Genome Res. 2005;15:901–913. [PubMed]
10. Cooper GM, et al. Single-nucleotide evolutionary constraint scores highlight disease-causing mutations. Nat Methods. 7:250–251. [PMC free article] [PubMed]
11. Prasad R, et al. Structure and expression pattern of human ALR, a novel gene with strong homology to ALL-1 involved in acute leukemia and to Drosophila trithorax. Oncogene. 1997;15:549–560. [PubMed]
12. Issaeva I, et al. Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth. Mol Cell Biol. 2007;27:1889–1903. [PMC free article] [PubMed]
13. Glaser S, et al. Multiple epigenetic maintenance factors implicated by the loss of Mll2 in mouse development. Development. 2006;133:1423–1432. [PubMed]
14. Tonoki H, Saitoh S, Kobayashi K. Patient with del(12)(q12q13.12) manifesting abnormalities compatible with Noonan syndrome. Am J Med Genet. 1998;75:416–418. [PubMed]